Iron Drugs Research Articles

Efficiency of ferrotherapy when using different groups of iron drugs in patients with Helicobacter pylori

To date, a number of scientific studies are being conducted in the world devoted to the study of various variants of the manifestation of helicobacteriosis. Special attention should be paid to studies on the pathogenesis of iron drugs (ID) in helicobacteriosis and the role of eradication therapy in improving the effectiveness of iron therapy. Despite the fact that there are results of numerous studies confirming the role of HP in the development of ID, there are still unresolved issues related to determining the exact indications for specific therapy aimed at eradicating this infection in cases where patients with clinical and laboratory signs of ID do not have obvious symptoms damage to the gastric mucosa.

Therapeutic correction of anemia in patients with chronic heart failure of ischemic origin with iron’s drugs in combination with quercetin

The aim of the study was to evaluate the effectiveness of anemia's correction in patients with chronic heart failure of ischemic genesis with iron's drugs in comparison with their combination with quercetin based clinical, cardiohemodynamic characteristic, indicators of erythropoiesis and cytokines. Materials and methods. Tere were examinated 120 patients with chronic heart failure due to iscemic heart disease and anemia. Chronic heart failure FC II diagnosed in 49 pations, III FK – 42 and FC IV – 29. Patients with CHF and anemia were divided in 2 groups. 1 group recieved standart therapy and iron’s drugs, the 2 group was additionally assigned quercetin. Hemoglobin, serum iron, erythropoetin and ferritin levels were evaluated. Results. After the therapy, the level of erythrocytes, hemoglobin, hematocrit, serum iron in the first group increased by 5.3, 20.3, 12.8, 40.2 %, respectively, in the II group – by 9.2, 25.6, 14.2 and 62.4 % respectively. The level of erythropoietin before the onset of therapy in both groups significantly exceeded the control indices. After treatment it significantly decreased in the I group by 20.4 %, in II – by 28.2 %. A significant increase of the level of tumor necrosis factor-α, interleukin-1β was determined in both groups of patients with chronic heart failure and anemia, In first group level of tumor necrosis factor -α significantly decreased by 14.2 %, interleukin-1β – on 6.5 %, in II group – by 26.6 % and 28.1 % respectively after the treatment. In the first group the end-diastolic diameter was significantly decreased by 7.7 %, the end-diastolic volume by 9.5 %, the end-systolic diameter by 7.9 %, the end systolic volume by 7.5 %, the ejection fraction increased by 14.4 % and indicators of a 6-minute walk test by 19.4 %, quality of life parameters by 24.2 %, in II group the end diastolic diameter decreased by 11.3 %, the end diastolic volume by 10.2 %, the end systolic diam, eter by 9.4 %, the end systolic volume by 13.6 %, the ejection fraction increased by 18.3 %, the distance of 6-minute walk test improved by 34.0 % the quality of life parameters by 32.9 %. Conclusions. It has been detected, that anemia’s correction in patients with CHF, who received combination of standart treatment with iron’s drugs accompanied by an increase in the level of erythrocytes, hemoglobin, iron, and decreased level in the initially increased levels of erythropoetin, ferritin, tumor necrosis factor-α, interleykin-1β. Favorable changes in erythropoiesis were accompanied by a positive dynamics of the morphofunctional parameters of the myocardium, the distance during the 6-minute walk test and the quality of life indicators. Quercetin, included in the scheme of therapy of patients with chronic heart faiulure and anemic syndrome, potentiated hematopoietic and hemodynamic effects of therapy.

Determination of Iron Content in Iron Deficiency Drugs by UV-Visible Spectrophotometer

The objective of this work was to validate a simple, precise and accurate spectrophotometric method for the determination of iron in the iron deficiency drugs, namely are Feroglobin B12, Ferose-F and Ferose. The proposed method is based on the reaction of iron with ammonium thiocyanate after the wet digestion of the drugs under study with HNO 3 and H 2 O 2 . Effects of pH, temperature, standing time and thiocyanate concentration on the determination of iron in drugs containing iron have been investigated. The λ max was 430 nm and the molar absorptivity of 0.0399 L mol -1 cm -1 . The linear regression was in the range 0.5 - 60 μg/mL for iron content in hemoglobin. The detection limit and the limit of quantification were found to be 0.040 and 0.122 µg mL -1 for the iron respectively, and with a linear regression correlation coefficient of 0.998. Recovery measurements ranged from 99.63-100.20%. This method is simple and fast can be used for the determination of iron in the iron deficiency drugs in pharmaceutical laboratories. DOI: http://dx.doi.org/10.17807/orbital.v9i3.953

Determination of μmol l-1 level of iron (III) innatural waters and total iron in drugs byflow injection spectrophotometry

The equilibrium problems, characterized by recurring end-points, involved in the reaction of iron (III) with iodide make the batch iodometric determination of iron (III) unsuitable. Since the flow injection determination does not require attainment of steady state either for mixing of reagents or for the chemical reaction, the iodometric determination has been accurately and precisely performed using this technique in the present work. This method does not require any special reagent, including chelating agents or those which are loxic, and has a limit of detection of 0.2 μmol l-1 (11 μg l-1) of iron (III). The interference of fluoride has been avoided by adding zirconyl nitrate to the test sample solution, and of copper (II) by complex formation with 2-mercaptobenzoxazole. The method has been applied to determine iron (III) in natural waters, and total iron in drugs.

Determination of mumoll-1 level of iron (III) in natural waters and total iron in drugs by flow injection spectrophotometry

Determination of mumoll-1 level of iron (III) in natural waters and total iron in drugs by flow injection spectrophotometry

1-Phenyl-3-thiobenzoyl thiocarbamide as a sensitive reagent for the determination of iron

A highly sensitive reagent, 1-phenyl-3-thiobenzoyl thiocarbamide (PTT) is used for the extraction and spectrophotometric determination of iron at trace level. The yellowish-red coloured Fe-PTT complex is formed at room temperature and maximum colour intensity is attained in 60 min. It is extractable into chloroform and shows maximum absorption at 410 nm. Beer's law is followed in the range of 2–20 ng Fe/ml. The sensitivity of determination (Sandell's) is 0.0266 ng/cm2 and molar absorptivity is 2.094×106l·mol−1·cm−1. Many common ions are tolerated to a large ratio. The method has been utilized to determine iron in drugs, water and ores.

Collaborative Study of a Spectrophotometric Determination of Ferric, Ferrous, and Total Iron in Drugs by Reaction with α,α′-Dipyridyl

A spectrophotometric method for determining Fe2+, Fe3+, and total Fe in drugs has been developed, using alpha,alpha'-dipyridyl as the colorimetric reagent. The method is applicable to tablets elixirs, injectables, and bulk powder. Eight collaborates analyzed a synthetic iron preparation and 7 commercial samples. For the synthetic iron preparation, the average recovery was 100.3% and the coefficient of variation was 1.02%. For 7 commercial samples, the average coefficient of variation was 1.44%. The method has been adopted as official first action.

Spectrophotometric Determination of Ferric, Ferrous, and Total Iron in Drugs by Reaction with α,α′-Dipyridyl

The drug sample is dissolved in 0.2N HCl to yield a final concentration of 30 mug Fe/ml, an aliquot is reacted with alpha,alpha-dipyridyl, and the pH is adjusted with an acetate buffer. For Fe(II), the color intensity is measured at 523 nm. For total iron, ascorbic acid is added to a separate aliquot of the sample solution, reducing all the iron present to Fe(II), which is then reacted with alpha,alpha'-dipyridyl, diluted to volume, and read at 523 nm. The Fe(III) content is determined by subtracing Fe(II) from total iron. This method is applicable to iron-containing drugs and drug dosage forms.